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Abstract 
Reproducible science requires transparent reporting. The ARRIVE guidelines were originally 
developed in 2010 to improve the reporting of animal research. They consist of a checklist of 
information to include in publications describing in vivo experiments to enable others to scrutinise the 
work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite 
considerable levels of endorsement by funders and journals over the years, adherence to the 
guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in 
animal research publications have not been achieved.  
Here we introduce ARRIVE 2019. The guidelines have been updated and information reorganised to 
facilitate their use in practice. We used a Delphi exercise to prioritise the items and split the guidelines 
into two sets, the ARRIVE Essential 10, which constitute the minimum requirement, and the 
Recommended Set, which describes the research context. This division facilitates improved reporting 
of animal research by supporting a stepwise approach to implementation. This helps journal editors 
and reviewers to verify that the most important items are being reported in manuscripts. We have also 
developed the accompanying Explanation and Elaboration document that serves 1) to explain the 
rationale behind each item in the guidelines, 2) to clarify key concepts and 3) to provide illustrative 
examples. We aim through these changes to help ensure that researchers, reviewers and journal 
editors are better equipped to improve the rigour and transparency of the scientific process and thus 
reproducibility. 
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Why good reporting is important 
In recent years issues about the reproducibility of research findings have raised considerable concern 
among scientists, funders, research users and policy makers [1-3]. Important contributing factors 
identified include flawed study design and analysis, variability and inadequate validation of reagents 
and other biological materials, insufficient reporting of methodology and results, and barriers to access 
data [4]. A number of initiatives have been developed to improve the reproducibility of scientific 
research, from funders’ open access policies [5], through to alternative peer review models [6], and the 
development of infrastructure to promote study preregistration and data sharing [7].  
Transparent reporting is an essential first step for any initiative focusing on reproducibility. Without 
this, the methodological rigour of the studies cannot be adequately scrutinised, the reliability of the 
findings cannot be assessed, and the work cannot be repeated or built upon by others. Despite the 
development of specific reporting guidelines for preclinical and clinical research, evidence suggests 
that scientific publications often lack key information and that there continues to be considerable 
scope for improvement [8-14]. Animal research is a good case in point, where poor reporting impacts 
on the development of therapeutics and irreproducible publications can spawn an entire field of 
research, or trigger clinical studies, subjecting patients to interventions unlikely to be effective [2, 15, 
16].  
In an attempt to improve the reporting of animal research, the ARRIVE guidelines were published in 
2010. The guidelines consist of a checklist of the information that should be included in any 
manuscript describing animal-based research, to ensure that the research is described in a 
comprehensive and transparent manner [17-27]. In the nine years since publication, the ARRIVE 
guidelines have been endorsed by more than a thousand journals from across the life sciences. 
Endorsement typically includes advocating their use in guidance to authors and reviewers. However, 
only a small number of journals actively enforce compliance; recent studies have shown that important 
information as set out in the ARRIVE guidelines is still missing from most publications sampled. This 
includes randomisation (reported in only 30-40% of publications), blinding (reported in only 
approximately 20% of publications), sample size justification (reported in less than 10% of 
publications) and animal characteristics (all basic characteristics reported in less than 10% of 
publications) [28-30].  
Evidence suggests two main factors limit the impact of the guidelines. The first is the extent to which 
editorial and journal staff are involved in enforcing reporting standards. A randomised controlled trial at 
PLOS ONE, for example, demonstrated that a request by journal staff to include a completed ARRIVE 
checklist in the manuscript submission process did not improve the disclosure of information in 
published papers [31]. In contrast, other studies using reporting checklists with more editorial follow up 
have shown a marked improvement in the nature and detail of the information included in publications 
[32-34]. Providing the level of journal or editorial input required to ensure compliance with all the items 
of the ARRIVE guidelines is unlikely to be sustainable for most journals because of the resources 
needed. Requesting adherence with all items at once, with no consideration of their relative 
importance might also be perceived as too prescriptive and further complicate the task. 
The second issue is that researchers and other individuals and organisations responsible for the 
integrity of the research process are not sufficiently aware of the consequences of incomplete 
reporting. There is some evidence that awareness of ARRIVE is linked to the use of more rigorous 
experimental design standards [35], but there is also evidence that researchers are unaware of the 
much larger systemic bias in the publication of research and in the reliability of certain findings and 
even of entire fields [31, 36-38]. This lack of understanding affects how experiments are designed and 
grant proposals prepared, how animals are handled and data recorded in the laboratory, and how 
manuscripts are written by authors or assessed by journal staff, editors and reviewers. 
Approval for experiments involving animals is generally based on a harm-benefit analysis, weighing 
the harms to the animals involved against the benefits of the research to society. If the research is not 
reported in enough detail, even when conducted rigorously, the benefits may not be realised, and the 
harm-benefit analysis and public trust in the research are undermined [39]. As a community, we must 
do better to ensure that where animals are used the research is well designed and analysed, and 
transparently reported. Here we introduce the revised ARRIVE guidelines, referred to as ARRIVE 
2019. The information included has been updated, extended and reorganised to facilitate the use of 
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the guidelines, helping to ensure that researchers, editors and reviewers, as well as other relevant 
journal staff, are better equipped to improve the rigour and reproducibility of animal research. 
 
Introducing ARRIVE 2019 
The revision of the ARRIVE guidelines has been undertaken by a new international working group – 
the authors of this publication. Our expertise comes from across the life sciences community, including 
funders, journal editors, statisticians, methodologists and researchers from academia and industry. We 
have improved the clarity of the guidelines, prioritised the items, added new information and generated 
the accompanying Explanation and Elaboration document to provide context and rationale for each 
item [40]. New additions comprise inclusion and exclusion criteria, which are a key aspect of data 
handling and prevent the ad hoc exclusion of data [41]; protocol registration, a recently emerged 
approach which promotes scientific rigour and encourages researchers to carefully consider the 
experimental design and analysis plan before any data are collected [42]; and data access, in line with 
the FAIR Data Principles [43]. Table S1 summarises the changes. 
The most significant departure from the original guidelines is the classification of items into two 
prioritised groups, as shown in Tables 1 and 2. There is no ranking within each group. The first group 
is the “ARRIVE Essential 10” which describes information that is the basic minimum to include in a 
manuscript, as without this information reviewers and readers cannot confidently assess the reliability 
of the findings presented. It includes the study design, sample size, measures to reduce subjective 
bias such as randomisation and blinding, outcome measures, statistical methods, experimental 
animals used, experimental procedures and results. The second group, referred to as the 
“Recommended Set” adds context to the study described. This includes the ethical statement, 
declaration of interest, protocol registration and data access, as well as more detailed information on 
the methodology such as animal housing, husbandry, care and monitoring. Items on abstract, 
background, objectives, interpretation and generalisability also describe what to include in the more 
narrative parts of a manuscript. The prioritisation was derived from a Delphi exercise [44] to rank items 
according to their relative importance for assessing the reliability of research findings. The Delphi 
panel included the working group in addition to external stakeholders, to ensure maximum diversity in 
fields of expertise and geographical location. Demographics of the Delphi panel and full methods and 
results are presented in Supporting Information S2 and S3.  
The classification of the items into two groups is intended to facilitate the improved reporting of animal 
research by allowing an initial focus on the most critical issues. This better allows journal staff, editors 
and reviewers to verify that the items have been adequately reported in manuscripts. The first step 
should be to ensure compliance with the ARRIVE Essential 10 as a minimum requirement. Items from 
the Recommended Set can then be added over time and in line with specific editorial policies until all 
the items are routinely reported in all manuscripts.  
Although the guidelines are written with researchers and journal editorial policies in mind, it is 
important to stress that researchers alone should not have to carry the burden of responsibility for 
transparent reporting. Funders, institutions and publishers all have a responsibility to ensure that the 
appropriate training, workflows and practices are in place to support researchers in their different 
roles. In particular, institutions and other research performing organisations, both public and private, 
as well as publishers, have a key role to play in building capacity and championing the behavioural 
changes required to improve reporting practices. 
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ARRIVE Essential 10 
Study design 1 For each experiment, provide brief details of study design including: 
a. The groups being compared, including control groups. If no control group has been used, 
the rationale should be stated. 
b. The experimental unit (e.g. a single animal, litter, or cage of animals). 
Sample size 2 a. Specify the exact number of experimental units allocated to each group, and the total 
number in each experiment. Also indicate the total number of animals used. 
b. Explain how the sample size was decided. Provide details of any a priori sample size 
calculation, if done. 
Inclusion and 
exclusion criteria 
3 a. Describe any criteria established a priori for including and excluding animals (or 
experimental units) during the experiment, and data points during the analysis. 
b. For each experimental group, report any animals, experimental units or data points not 
included in the analysis and explain why. 
c. For each analysis, report the exact value of N in each experimental group. 
Randomisation 4 Describe the methods used:  
a. To allocate experimental units to control and treatment groups. If randomisation was used, 
provide the method of randomisation.  
b. To minimise potential confounding factors such as the order of treatments and 
measurements, or animal/cage location. 
Blinding 5 Describe who was aware of the group allocation at the different stages of the experiment 
(during the allocation, the conduct of the experiment, the outcome assessment, and the data 
analysis). 
Outcome 
measures 
6 a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or 
behavioural changes).  
b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome 
measure that was used to determine the sample size. 
Statistical 
methods 
7 a. Provide details of the statistical methods used for each analysis. 
b. Specify the experimental unit that was used for each statistical test.   
c. Describe any methods used to assess whether the data met the assumptions of the 
statistical approach. 
Experimental 
animals 
8 a. Provide details of the animals used, including species, strain and substrain, sex, age or 
developmental stage, and weight. 
b. Provide further relevant information on the provenance of animals, health/immune status, 
genetic modification status, genotype, and any previous procedures. 
Experimental 
procedures  
9 For each experimental group, including controls, describe the procedures in enough detail to 
allow others to replicate them, including:  
a. What was done, how it was done and what was used. 
b. When and how often. 
c. Where (including detail of any acclimation periods). 
d. Why (provide rationale for procedures). 
Results 
 
10 For each experiment conducted, including independent replications, report: 
a. Summary/descriptive statistics for each experimental group, with a measure of variability 
where applicable. 
b. If applicable, the effect size with a confidence interval. 
 
Table 1. ARRIVE Essential 10 
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Recommended Set 
Abstract 11 Provide an accurate summary of the research objectives, animal species, strain and sex, key 
methods, principal findings, and study conclusions. 
Background 
 
12 a. Include sufficient scientific background to understand the rationale and context for the 
study, and explain the experimental approach. 
b. Explain how the animal species and model used address the scientific objectives and, 
where appropriate, the relevance to human biology. 
Objectives 13 Clearly describe the research question, research objectives and, where appropriate, specific 
hypotheses being tested. 
Ethical statement 14 Provide the name of the ethical review committee or equivalent that has approved the use of 
animals in this study and any relevant licence or protocol numbers (if applicable). If ethical 
approval was not sought or granted, provide a justification. 
Housing and 
husbandry 
15 Provide details of housing and husbandry conditions, including any environmental enrichment. 
Animal care and 
monitoring 
 
16 a. Describe any interventions or steps taken in the experimental protocols to reduce pain, 
suffering and distress. 
b. Report any expected or unexpected adverse events. 
c. Describe the humane endpoints established for the study and the frequency of monitoring. 
Interpretation 
/scientific 
implications 
17 a. Interpret the results, taking into account the study objectives and hypotheses, current theory 
and other relevant studies in the literature. 
b. Comment on the study limitations including potential sources of bias, limitations of the 
animal model, and imprecision associated with the results. 
Generalisability 
/translation 
18 Comment on whether, and how, the findings of this study are likely to generalise to other 
species or experimental conditions, including any relevance to human biology (where 
appropriate). 
Protocol 
registration 
19 Provide a statement indicating whether a protocol (including the research question, key design 
features, and analysis plan) was prepared before the study, and if and where this protocol was 
registered. 
Data access 20 Provide a statement describing if and where study data are available.  
Declaration of 
interests 
21 a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, 
this should be stated. 
b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, 
analysis and reporting of the study. 
 
Table 2. ARRIVE Recommended Set 
 
Conclusion 
Transparent reporting is clearly essential if animal studies are to add to the knowledge base and 
inform future research, policy and clinical practice. ARRIVE 2019 prioritises the reporting of 
information related to study reliability. This enables research users to assess how much weight to 
ascribe to the findings, and in parallel promotes the use of rigorous methodology in the planning and 
conduct of in vivo experiments [35], thus increasing the likelihood that the findings are reliable, and 
ultimately, reproducible.  
The intention of ARRIVE 2019 is not to supersede individual journal requirements but to promote a 
harmonised approach across journals to ensure that all manuscripts contain essential information 
needed to appraise the research. The step-by-step approach is in line with current practice by a 
number of journals who recommend that authors not only refer to the ARRIVE guidelines while 
preparing their manuscript, but also implement a checklist with a core set of items. Journals usually 
share a common objective of improving the methodological rigour and reproducibility of the research 
they publish, but different journals emphasise different pieces of information [45-47]. Here we propose 
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an expert consensus on information to prioritise. This will provide clarity for authors, facilitate transfer 
of manuscripts between journals, and accelerate an improvement of reporting standards. 
Concentrating the efforts of the research and publishing communities on the ARRIVE Essential 10 
items provides a manageable approach to evaluate reporting quality efficiently and assess the effect 
of interventions and policies designed to improve the reporting of animal experiments. It also provides 
a starting point for the development of automated or semi-automated artificial intelligence tools that 
can detect missing information rapidly [48].  
Improving reporting is a collaborative endeavour and concerted effort from the biomedical research 
community is required to ensure maximum impact. We welcome collaboration with other groups 
operating in this area, and feedback on ARRIVE 2019 and our implementation strategy.  
 
Supporting information 
S1 Table: Noteworthy changes in ARRIVE 2019, compared to ARRIVE 2010 
S2 Delphi methods and results 
S3 Delphi data 
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S1 Table: Noteworthy changes in ARRIVE 2019, compared to ARRIVE 2010 
ARRIVE 2019 ARRIVE 2010 Reason for change 
All items All items We reordered items and split them in two sets based on their importance to assess the reliability of the study. There is no 
ranking within each set, items are ordered logically. 
ARRIVE Essential 10 
Item 1 – Study design Item 6 – Study design We removed the reference to steps taken to minimise the effects of bias (formerly subitem 6b). All information about 
randomisation is now in item 4 and all information about blinding is now in item 5. 
Item 2 – Sample size Item 10 – Sample size We clarified that the number of experimental units might be different from the number of animals. Independent replications 
are now mentioned with the results (item 10) to prevent any confusion with biological replicates. 
Item 3 – Inclusion and 
exclusion criteria 
Item 15 – Numbers 
analysed 
We added a new subitem on a priori inclusion and exclusion criteria, evidence shows that ad hoc exclusion of data can lead 
to false positive results [1]. We clarified that the N number in each analysis might be different from the number of animals. 
We renamed the item to better reflect content. 
Item 4 – 
Randomisation  
Item 11 – Allocating 
animals to 
experimental groups 
All references to randomisation were consolidated in this item for clarity. We reworded the text to include the randomisation 
procedure which was covered separately in the study design (formerly item 6). We clarified that experimental units are 
allocated to group, rather than animals.  
Item 5 – Blinding  Item 6 – Study design Blinding was included in the original guidelines as part of the study design (formerly subitem 6b), we have added more text 
in a new item to highlight its importance and encourage greater specificity. 
Item 6 – Outcome 
measures 
Item 12 – 
Experimental 
outcomes 
We clarified that all outcome measures should be reported, and added a subitem to highlight the need to identify a primary 
outcome measure for hypothesis-testing studies. 
We changed the item name to 'outcome measures' because of concerns within the group that the term 'experimental 
outcomes' could be ambiguous. 
Item 7 – Statistical 
methods 
Item 13 – Statistical 
methods 
We removed a reference to unit of analysis, which is often poorly understood and used the term experimental unit for 
consistency throughout the guidelines. 
Item 8 – experimental 
animals 
Item 8 – experimental 
animals 
We clarified the wording and removed examples to streamline the guidelines, further details are discussed in the supporting 
E&E document [2]. 
Item 9 – Experimental 
procedures 
Item 7 – Experimental 
procedures 
We encouraged greater specificity by stating that procedures should be described in enough detail to allow others to 
replicate them. We removed examples to streamline the guidelines, further details are discussed in the supporting E&E 
document [2]. 
Item 10 – Results  Item 16 – outcomes 
and estimation 
We expanded this item to provide more explicit guidance on reporting results. The name of the item was changed from 
'outcomes and estimations' to 'results' for clarity and prevent confusion with item 6 – outcome measures. 
Item removed Item 14 – Baseline 
data 
This item overlapped with item 8 – Experimental animals and the two items where combined, with further details provided in 
the supporting E&E document [2]. 
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 ARRIVE Recommended Set 
Item 11 – Abstract  Item 2 – Abstract We specified that the sex of animals used should be included the abstract, empirical evidence suggests an endemic male 
bias in biomedical research [3]. 
Item 12 – Background  Item 3 – Background  We clarified the wording and removed examples to streamline the guidelines, further details are discussed in the supporting 
E&E document [2]. 
Item 13 – Objectives Item 4 – Objectives We removed a reference to primary and secondary objectives as it would not apply to exploratory studies, and added a 
requirement to describe the research question, which is relevant to all study types. 
Item 14 – Ethical 
statement 
Item 5 – Ethical 
statement 
We removed reference to UK legislation to make this item relevant for an international audience. We added specification of 
the relevant licence or protocol numbers to provide accountability and promote transparency. 
Item 15 – Housing 
and husbandry 
Item 9 – Housing and 
husbandry 
We moved the subitem on welfare-related assessments and interventions to item 16 – Animal care and monitoring. We 
removed examples to streamline the guidelines, further details are discussed in the supporting E&E document [2]. 
Item 16 – Animal care 
and monitoring 
Item 17 – Adverse 
events 
We added a new subitem to encourage the reporting of humane endpoints and monitoring, and changed the name of the 
item to animal care and monitoring to better reflect content. 
Item 17 – 
Interpretation/scientific 
implications 
Item 18 – 
Interpretation/scientific 
implications 
We removed subitem c “Describe any implications of your experimental methods or findings for the replacement, 
refinement or reduction (3Rs) of the use of animals in research”. This item is not relevant to all animal studies and further 
details have been provided in the supporting E&E document [2]. 
Item 18 – 
Generalisability/ 
translation 
Item 19 – 
Generalisability/ 
translation 
We simplified and clarified the wording. 
Item 19 – Protocol 
registration 
New item We added a new item on registering key aspects of the protocol. Empirical studies have shown up to 50% of outcomes 
which are measured are not reported [4]. This selective outcome reporting bias leads to an overstatement of biological 
effects. 
Item 20 – Data access New item We added a new item on data access to encourage authors to provide a data sharing statement describing how others can 
gain access to the data on which the paper is based. 
Item 21 – Declaration 
of interests 
Item 20 – Funding We added a new sub-item on declaring potential conflicts of interest. We added the specification of the role of the funder(s) 
in the ‘design, analysis and reporting of the study’. This information allows the reader to assess any competing interests, 
and any potential sources of bias. 
We renamed the item to better reflect content. 
Item removed Item 1 – Title  We removed this item as it provided no specific guidance on what to include in the title. 
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S2 – Delphi methods and results 
 
1 Methods 
1.1 Development of the revised checklist 
For each subitem of ARRIVE 2010, the NC3Rs summarised the evidence justifying its inclusion in the guidelines 
and any indication of a need for revision. The working group then met for a two-day meeting in November 2017 in 
London, to review this information, discuss the addition of new items and agree on the strategy to go forward. We 
agreed to update the guidelines, develop an explanation and elaboration (E&E) document for ARRIVE 2019 [1] and 
prioritise the items to facilitate the uptake of the revised guidelines [2]. After the meeting, each item was allocated 
to at least two members of the working group to develop the item’s explanation in more detail and refine the item’s 
wording. Further iterations of the checklist were achieved by email discussion within the whole group.  
The Delphi exercise was designed to achieve consensus on prioritising items of the ARRIVE guidelines. 
The objective was to allocate the 22 items into two or three shortlists with different levels of priority, and relatively 
even distribution within each set.  
1.2 Recruitment of the Delphi expert panel 
Ethical approval for this study was obtained from the University of Bristol, Faculty of Science Research Ethics 
Committee (ID 66625). 
The panel consisted of the ARRIVE Working Group and external stakeholders nominated by the Working Group, 
with suitable expertise on the quality of animal research or its reporting. We aimed to gather a diverse panel of 
experts, both in terms of field of expertise and geographical location. 
Panel members consented to take part by following a link in the invitation email to the first round. 
1.3 The Delphi process 
There were three iterations of the questionnaire in total [3], and these were managed using the Comet Initiative 
DelphiManager platform (http://www.comet-initiative.org/DelphiManager/). Data collection took place June to 
November 2018. Panel members received an email invitation at the start of each round with a link to the online 
questionnaire. They were allowed three weeks to complete the questionnaire, with email reminders at day 7 and 
day 14. If they did not respond within the time frame they were excluded from that round, however they were 
invited to take part in the subsequent rounds of the Delphi. 
Each of the 22 items of the revised ARRIVE guidelines was evaluated against the statement: 
“How important is this piece of information for assessing the reliability of results in an animal research 
paper?” 
Panel members scored each item on a scale of 1 – 9, where 1 was least important and 9 was most important.  
The questionnaire presented in round 1 included free-text fields to provide reasoning for the score given to each 
item. Individual justifications were collated, summarised and presented to the whole panel in round 2. 
In round 2, panel members were asked to provide a justification if their score for a particular item had changed 
between round 1 and round 2. Similarly, this information was summarised and presented to the whole panel in 
round 3. 
Following rounds 1 and 2, the scores for each item were analysed and a structured summary consisting of a 
histogram showing the dispersal of the scores in the entire panel was prepared. This summary was presented with 
a new iteration of the questionnaire at the next round, where panel members were asked to re-score the items. In 
round 2 and 3, panel members’ own scores from the previous round were also displayed for each item. 
To encourage a wider dispersal of scores, in the final round (round 3) panel members were asked to follow two 
rules while scoring items: 
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 to score no more than ten items in the top range (7 – 9) 
 to score no fewer than six items in the bottom range (1 – 3)  
In the final dataset we excluded data entries which had not followed these rules, allowing for a deviation of ±1 item 
in each range. 
1.4 Addition of new ARRIVE items 
In the first round of the Delphi, we asked the panel to suggest new items that they believed should be included in 
the revised guidelines. The threshold for inclusion was defined a priori; for a new item to be considered, it would 
have to be suggested by at least 10% of the panel. The panel also had the opportunity to provide general feedback 
at the end of the survey. 
1.5 Criteria for allocating items to sets 
The plan to achieve consensus was defined a priori and two options were considered. The first option was to 
allocate the items in three sets, based on each item’s median score and a minimum of 70% of the panel scoring the 
item within the same range. Score ranges were defined as follows: 
 top range (7 – 9) 
 middle range (4 – 6) 
 bottom range (1 – 3) 
 
Should the panel fail to reach agreement using the first option, the second option was to allocate the items in two 
sets and allocate items with a median score of 7 or above and an agreement level greater than 70% to the first set, 
and all other items to the second set.  
Once data collection was completed, the ARRIVE working group met via videoconference to review the results and 
discuss the allocation of items into sets. As only 10 of 22 items reached the predefined agreement consensus of 
70% (see supplementary information S3 – Delphi results), the second option was used to allocate items into two 
sets. 
 
2 Results  
2.1 Composition of the Delphi expert panel 
One hundred experts were invited to participate in the Delphi exercise, 73 accepted the invitation and 71 
participated in the final round (see Figure 1). Ten data entries, which did not follow data dispersal rules were 
excluded, 61 data entries were therefore included in the final score analysis. 
 
Figure 1. Delphi panel included at each stage of the Delphi exercise. 
Demographics of the panel are presented in Table 2. 
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2.2 Suggestions for new items and feedback on existing items 
18 panel members suggested a total of 31 new items (see supplementary information S3 – Delphi data). No new 
item suggestion met the 10% threshold for inclusion in the revised guidelines.  
Feedback on the wording of existing items was considered by the working group in the drafting of the revised items 
and the drafting of the accompanying E&E document.  
Feedback from the Delphi panel indicated that the item on number analysed was misunderstood and confused with 
the item on sample size. For clarity, the item on number analysed was incorporated to the item on inclusion and 
exclusion criteria in further iterations of the guidelines. This reduced the number of items to 21. 
 
2.3 Scores for each Delphi round 
The scores assigned to each item in rounds 1, 2 and 3 are shown in Figure 2. 
 
Figure 2. Item scores for each of the three Delphi rounds. Box and whisker plots of the panel members’ scores for 
the 22 items. Round 1: n=71-73, round 2: n=70-71, round 3: n=61, the exact sample size for each item in each 
round is provided in supplementary information S3 – Delphi data. Data plotted as median, interquartile range, 
minimum, maximum and outliers using https://www.displayr.com/. Raw data available at https://osf.io/8xjdr/. 
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2.4. Allocation of items to sets 
The allocation of items into sets is presented in Table 1. Eight items were shortlisted based on the a priori criterion 
(score in the top range and over 70% agreement within the panel). Three further items scoring in the top range 
were added to the shortlist following discussion within the working group. 
Note that 11 items were allocated to set 1 but the combination of inclusion and exclusion criteria and numbers 
analysed in subsequent iterations of the guidelines reduced that number to 10 shortlisted items. 
Set Item Score % scores in the top range Reasoning 
Set 1 
Study design 9 (9-9) 95  
All items met pre-
defined threshold 
(70%) for Set 1. 
Sample size 9 (9-9) 92 
Experimental procedures 9 (9-9) 87 
Outcome measures 9 (8-9) 85 
Experimental animals 9 (8-9) 84 
Blinding 9 (7-9) 77 
Randomisation 9 (6-9) 70 
Statistical methods 8 (6-9) 72 
Numbers analysed 8 (6-9) 69 
Median score in the 
top range. Inclusion and exclusion criteria 8 (6-9) 66 
Results 8 (6-9) 59 
Set 2 
 
Objectives  6 (4-8) 33 
Median score outside 
the top range. 
Housing and husbandry 6 (3-6) 21 
Animal care and monitoring 5 (3-6) 10 
Ethical statement 3 (3-6) 20 
Abstract 3 (2-6) 16 
Data Access 3 (3-6) 11 
Background 3 (3-6) 8 
Protocol registration 3 (3-4) 7 
Interpretation/Scientific 
implications 3 (3-5) 2 
Declaration of interests 3 (3-6) 2 
Generalisability/Translation 3 (2-3) 0 
Table 1. Allocation of the 22 items into two sets. Scores are displayed as median and interquartile range (IQR), 
n=61.
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Primary country of work  Years of relevant experience  Professional role 
UK 27 1   - 10 13 In vivo researcher 32 
USA 11 11 - 20 27 Journal editor 20 
Canada 7 21 - 30 22 Statistician 6 
Brazil 5 31 - 40 8 Professor 5 
Australia 3 41 - 50 3 Systematic review/ meta-researcher 4 
China 2  Veterinarian/ assistant veterinarian 4 
Germany 2 Career level Director of a lab animal facility 3 
Hong Kong 2 Principle Investigator 32 Former in vivo researcher 3 
Switzerland 2 Senior Staff 5 Educator 2 
The Netherlands 2 Associate Professor 4 Project manager 2 
Argentina 1 Director 4 Publisher 2 
Belgium 1 Staff Scientist 3 Reviewer of in vivo research 2 
India 1 Editor 2 Associate editorial director 1 
Japan 1 Executive Editor 2 Clinician 1 
Korea 1 Postdoctoral scientist 2 Director of research policy for a research funder 1 
Nigeria 1 Senior Editor 2 Director of research quality for a research funder 1 
Norway 1 Associate Director 1 Director of standards 1 
South Africa 1 Associate Editorial Director 1 Evidence synthesis specialist 1 
South Korea 1 Editorial Director 1 Head of experimental design for a research funder 1 
Sri Lanka 1 Head of Department 1 Mathematical biologist 1 
  Head of Laboratory and Research 1 Op-ed editor 1 
Sector of work Head of Policy 1 Policy analyst for a research funder 1 
Academia 45 Lab Animal Facility Director 1 Preclinical bioresearch quality & compliance  1 
Not-for-profit 7 Manager of Clinical Phenotyping Core 1 Researcher using in vitro methods and human subjects 1 
Industry 6 Managing Editor 1 Science administrator 1 
Publishing 6 Masters/PhD student 1 Scientific director 1 
Government 5 Mid-management 1 Scientist/manager 1 
Funding body 1 Policy analyst  1 Secretary of a 3Rs centre 1 
Media 1 Science Administrator 1 Senior program officer (science policy) 1 
Educator 1 Senior Manager 1  
Contract research company 1 No answer 3 
Table 2. Demographics of Delphi respondents (n = 73). Note that the total number of professional roles exceeds the number of panel members as they 
could select more than one role.
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